In 2022, a new Cancer Moonshot goal was announced—to reduce U.S. age-standardized cancer mortality rates by 50% over 25 years. Shiels and colleagues estimated the trends in cancer mortality during 2000 to 2019 for all cancers and the six leading types and revealed that cancer death rates declined overall by 1.4%/year from 2000 to 2015 but accelerated to 2.3%/year during 2016 to 2019. This decline was driven, in part, by regressions in lung (−4.7%/year, 2014–2019), colorectal (−2.0%/year, 2010–2019), and breast (−1.2%/year, 2013–2019) cancer mortality. However, trends for pancreatic, prostate, and liver cancers were less promising. Opportunities to prevent, detect, and treat common cancers that could further reduce population-level cancer death rates are also discussed.

See article, p. 1084.

Immune checkpoint inhibitor (ICI)–associated myocarditis is a rare event that carries a high mortality rate. Salem and colleagues developed a strategy to identify individuals with severe myocarditis that included screening for/managing concomitant...

You do not currently have access to this content.